ArticleDiscover oncology2025
Cervical metastasis of breast cancer: a case report and review of the literature.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cervical metastasis in breast cancer: A case report.Oncology letters · 2026Article
- Cervical Metastasis From Primary Breast Carcinoma: A Case Report and Review of Extragenital Tumors Involving the Uterine Cervix.Clinical case reports · 2026Article
- Metastasis of Breast Lobular Carcinoma to the Uterine Cervix: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Exploring the causal relationship between obesity, immune cell characteristics and cervical cancer risk using Mendelian randomization.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic breast cancer (BC) to the cervix is relatively rare among women with BC. Although the most common histopathological type of BC is invasive ductal carcinoma, invasive lobular carcinoma is more likely to metastasize to the female reproductive system due to its characteristic of the loss of E-cadherin. BC patients with metastasis to the cervix often exhibit no obvious clinical symptoms or may present with cervical-related symptoms, making early diagnosis challenging. CDK4/6 inhibitors, when combined with either aromatase inhibitors or fulvestrant, can enhance the prognosis for both premenopausal and postmenopausal women with recurrent ER-positive BC. We reported a patient with cervical metastasis of BC, who was ER-positive and HER2-negative. The patient received treatment with fulvestrant and abemaciclib after surgery for metastatic cervical cancer, achieving a progression-free survival of 31 months. We hope this case report will encourage more clinicians to prioritize gynecological examinations for patients with BC, particularly cervical cancer screening, in order to enhance the quality of life and prognosis for these individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.